RedHill Biopharma (RDHL) Depreciation and Depletion (2016 - 2022)
RedHill Biopharma has reported Depreciation and Depletion over the past 11 years, most recently at $491000.0 for Q4 2022.
- Quarterly Depreciation and Depletion rose 9.35% to $491000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2022, up 11.66% year-over-year, with the annual reading at $384000.0 for FY2025, 34.69% down from the prior year.
- Depreciation and Depletion was $491000.0 for Q4 2022 at RedHill Biopharma, roughly flat from $491000.0 in the prior quarter.
- Over five years, Depreciation and Depletion peaked at $617000.0 in Q2 2022 and troughed at $22000.0 in Q1 2018.
- The 5-year median for Depreciation and Depletion is $433000.0 (2020), against an average of $342350.0.
- Year-over-year, Depreciation and Depletion dropped 15.38% in 2018 and then skyrocketed 1209.09% in 2019.
- A 5-year view of Depreciation and Depletion shows it stood at $23000.0 in 2018, then soared by 1000.0% to $253000.0 in 2019, then surged by 86.96% to $473000.0 in 2020, then fell by 5.07% to $449000.0 in 2021, then rose by 9.35% to $491000.0 in 2022.
- Per Business Quant, the three most recent readings for RDHL's Depreciation and Depletion are $491000.0 (Q4 2022), $491000.0 (Q3 2022), and $617000.0 (Q2 2022).